E0418 Effect of EECP-integrated standard therapy for patients with stable coronary artery disease: a prospective, randomised, open-labelled and blind-endpoint study (PROBE-EECP trial). (17th November 2010)

• Record Type: Journal Article
• Authors: Zhimin, Du; Guifu, Wu; Qiang, Xie; Yan, Zhang; Daya, Yang; Li, Ling; Donghong, Liu; Lilong, Tang; Guangye, Chen; Hong, Ma
• Is Part Of: Heart. Volume 96(2010)Supplement 3
• Page Start: A129
• Page End: A129
• Publication Date: 2010-11-17
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/hrt.2010.208967.418
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Background: Enhanced External Counterpulsation (EECP) has been introduced as an noninvasive, effective and safe therapy for the management of ischaemic vascular diseases. Previously, researches had been focused on the mechanisms of EECP on vascular diseases. However, clinical data in this area are still relatively in paucity. Objective: To determine whether EECP-integrated standard therapy would reduce the major adverse cardiovascular events in patients with coronary artery diseases and improve the quality of life. Method: A total of 194 patients aged from 32 to 75 years old with coronary artery diseases from Sept. 2008 to Dec. 2009 in 4 hospitals affiliated to Sun Yat-sen University were enrolled into the trial. Subjects were randomised to be allocated either to EECP plus standard therapy group or standard therapy group, and followed for 0.5 to 1.5-year. The coronary artery disease in all patients was documented by coronary angiography, or a history of prior myocardial infarction or prior coronary revascularization. Patients in standard therapy group were treated with guideline-driven therapeutic strategy, and patients in EECP group were given 36 h of EECP in addition to the guideline-driven therapeutic strategy. Repeated EECP were prescribed to patients with any reoccurred ischaemic symptoms, or new ischaemia, or no symptoms in 12 months later. Follow-up visits were performed at 1, 3, 6, 12 months and each year therefore from the inclusion. Results: The primary composite endpoints of myocardial infarction, revascularisation, readmission to hospital due to stroke and ACS occurred in 6 of 104 (5.77%) patients in EECP group compared with 9 of 91 (9.89%) in standard therapy group (p<0.05). There was 1 death in both groups respectively. The incidence of minor skin damage was about 8% in EECP group, causing EECP therapy in 3 patients to be prematurely terminated. Conclusion: An EECP-integrated standard therapy significantly reduced major cardiovascular events in patients with documented coronary artery disease.